

February 13, 2019



## **Anixa Biosciences to Present at Moffitt Cancer Center's Business of Biotech Conference**

SAN JOSE, Calif., Feb. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that Dr. Amit Kumar, its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center's 13<sup>th</sup> Annual Business of Biotech Conference being held on February 22, 2019. The panel titled, "Navigating FDA Approvals for Cell Therapy" will focus on regulatory aspects of developing CAR-T and other cell therapies.

In addition to Dr. Kumar, other participants on the panel will include executives from Atara Biotherapeutics, Inc., Intellia Therapeutics, Inc., and Iovance Biotherapeutics, Inc.

The Business of Biotech Conference is an annual event held by Moffitt Cancer Center that brings together investors and experts from academia and industry interested in learning about the most advanced technologies in cancer research. For those interested in attending, please review the agenda and register here: <https://www.moffittip.com/business-of-biotech/>.


Dr. Kumar stated, "I am pleased to be attending and presenting at this conference. Moffitt Cancer Center is one of the top cancer centers in the world and a critical partner for Anixa. I am also pleased to be participating with colleagues from other leading CAR-T and cell therapy companies."

### **About Anixa Biosciences, Inc.**

[Anixa](#), a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is

available at [www.anixa.com](http://www.anixa.com).

**Forward-Looking Statements:** Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

 View original content to download multimedia <http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-moffitt-cancer-centers-business-of-biotech-conference-300794718.html>

SOURCE Anixa Biosciences, Inc.